The most likely explanation for the conflicting results of the two analyses is the different statistical program used by John Geddes and colleagues. Metaregression is a fairly new technique that is still evolving; it is suitable to explore reasons for heterogeneity, but the results must be interpreted with caution. 2 Graphical plots should always be drawn, 2 but in plots of either risk differences or log odds ratios no obvious linear relation with comparator dose is apparent (data presented on our website http://www.std-service.com/leucht.htm). We are not aware of any clear evidence to suggest that the complex Bayesian model implemented by Geddes and colleagues with the Markov Chain Monte Carlo program BUGS should be regarded as a gold-standard.
A reanalysis of our data with odds ratios instead of risk differences with Review Manager 4.1 showed that the advantage of the new drugs at comparator doses lower than 600 mg/day vanishes to a p value of 0·05 (odds ratio 0·65, 95% CI 0·42-1·00), but with relative risks the p value is again 0·03 (0·84, 0·71-0·98). We had made an a-priori protocol decision to use risk differences and we would not have found a posthoc change of measures appropriate. Risk differences have (mainly numerical) disadvantages, but also (mainly interpretational) advantages compared with other measures of effect size. Because of the latter, Warn and colleagues 3 have presented methods that allow the implementation of risk differences into BUGS. Numberneeded-to-treat statistics are commonly calculated as the inverse of the risk difference, so that reviewers need to return to this measure. Khanna and colleagues 4 have reported the findings of their large comparison of ziprasidone with chlorpromazine (n=307), and the clozapine trial by Lieberman and colleagues (n=164) 5 has also been published. Both trials indicate that the new antipsychotics could be more effective than the old ones.
We believe that the conflicting results between our analysis and that of Geddes and colleagues show that the data involved are not robust in terms of efficacy or tolerability. Our findings should be regarded as hypothesis generating not as treatment recommendations. Low-potency antipsychotics induce fewer extrapyramidal side-effects than high-potency antipsychotics. Even if future trials show advantages in terms of extrapyramidal side-effects with the new drugs versus low-potency antipsychotics, this superiority would probably be smaller than with highpotency antipsychotics. Differences in other side-effects associated with lowpotency antipsychotics, such as anticholinergic effects and sedation, also need to be established. Versitech are profit-seeking organisations, and they both hold the same view as CDC and BCCA-namely, to serve the public. HKU is committed to sharing its research results with society; locally, regionally, and internationally. We will continue to build up our research strength, but we cannot hope to share the benefits of our newly found knowledge if we do not properly manage our intellectual property rights. Cancer Agency (BCCA), who have reportedly proceeded to patent the genome of the coronavirus associated with severe acute respiratory syndrome (SARS). Specifically, the Commentary argued that the patent option would provide the two institutions "with more leverage in dealing with [HKU's] Versitech". Gold further argued that CDC and BCCA would "use the patent system to serve the public good". I wish to make clear that HKU is a research-led institution, committed to the public cause of higher education and benefiting society. Versitech is a technology transfer company, established in accordance with good practices of international universities to handle HKU's intellectual properties.
Lap-Chee Tsui
Neither HKU nor
Greece is iodine sufficient
Sir-In their Correspondence letter, Paolo Vitti and colleagues (April 5, p 1226) 1 incorrectly list Greece as an iodine deficient country (urinary iodine excretion <100 g/L). In the 1960s several areas of Greece were iodine deficient. 2 Since then though, the situation has improved. In 1999, 3 17 previously iodine deficient villages around Athens were studied; the urinary iodine concentrations were 109-164 g/L Cr in 13, and ranged from 43 g/L Cr to 70 g/L Cr in four.
In a representative area of southwestern Greece 4 great improvements in iodine intake have taken place. Specifically, 65% of city dwellers and 46% of villagers had urinary iodide excretion concentrations of greater than 100 g/L in 1996. In five of seven of the areas studied by Markou and colleagues, 4 a sufficient iodine intake was observed. In the remaining two isolated mountain villages (Kalavryta and Havari), mild iodine deficiency was noted.
In northwestern Greece, a historically iodine deficient mountainous region, two surveys were undertaken among schoolchildren, 5 one in 1994 and the other in 2001. In the first survey of 100 children, 5 the median urinary iodine concentration was 84 g/L, indicative of borderline iodine deficiency. In the second study, 5 7 years later, the median urinary iodine concentration of 300 children from the same area was 202 g/L, indicating sufficient iodine intake. More importantly, a rise in the frequency of autoimmune thyroiditis among these children was observed after the elimination of iodine deficiency. 5
